NCT03826875View on ClinicalTrials.gov

Poststroke Depression in Hemorrhagic Stroke

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

March 1, 2019

Primary Completion Date

May 7, 2025

Study Completion Date

May 7, 2025

Conditions
Stroke HemorrhagicDepression
Interventions
DRUG

Fluoxetine

Patients who suffered aneurysmal subarachnoid hemorrhage will be prescribed fluoxetine and evaluated for the preventative treatment of depression and health-related quality-of-life

DRUG

Placebo

Patients who suffered aneurysmal subarachnoid hemorrhage will be prescribed placebo and evaluated for the preventative treatment of depression and health-related quality-of-life

Trial Locations (1)

98104

Harborview Medical Center, Seattle

All Listed Sponsors
lead

University of Washington

OTHER

NCT03826875 - Poststroke Depression in Hemorrhagic Stroke | Biotech Hunter | Biotech Hunter